Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (8): 72-78.doi: 10.6040/j.issn.1671-7554.0.2022.0535

Previous Articles     Next Articles

Efficacy of ultrasound-guided sclerotherapy with pingyangmycin and lauromacrogol in 94 cases of cystic lymphatic malformation

WANG Wenjing1, LIU Boce1, BI Jianhai2, HUO Ran1,2   

  1. 1.Department of Plastic Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China;
    2. Department of Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China
  • Published:2022-07-27

Abstract: Objective To retrospectively analyze the efficacy and safety of ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol in the treatment of cystic lymphatic malformation(cLM). Methods A total of 94 cLM patients aged 0.5-43 years were enrolled, 75 of whom had onset before 2 years of age(32 cases of macrocystic type, 31 cases of microcystic type, and 31 cases of mixed type). Results The patients received an average of 2.8 times of treatments. During the follow-up of 3.7-39.2 months, the lesion volume reduction was 78.7%, the effective rate of symptom relief was 82.1%, and the satisfaction rate of patients and their families was 85.1%. Side effects occurred in 14 patients, but no serious adverse reactions such as pulmonary fibrosis or allergies were observed. Recurrence occurred in 7 patients, who received a second treatment and had good outcomes. Conclusion Ultrasound-guided percutaneous sclerotherapy with pingyangmycin and lauromacrogol is effective and safe in the treatment of cystic lymphatic malformation, and it is worthy of clinical promotion.

Key words: Cystic lymphatic malformation, Lymphatic malformation, Pingyangmycin, Lauromacrogol, Sclerotherapy

CLC Number: 

  • R622
[1] 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J].组织工程与重建外科杂志, 2019, 15(5): 277-317.
[2] Kulungowski AM, Patel M. Lymphatic malformations [J]. Semin Pediatr Surg, 2020, 29(5): 150971.
[3] Mäkinen T, Boon LM, Vikkula M, et al. Lymphatic malformations: genetics, mechanisms and therapeutic strategies [J]. Circ Res, 2021, 129(1): 136-154.
[4] Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: current cell ularand clinica linvestigations [J]. Otolaryngol Head Neck Surg, 2010, 142(6): 789-794.
[5] McCuaig CC. Update on classification and diagnosis of vascular malformations. [J]. Curr Opin Pediatr, 2017, 29(4): 448-454.
[6] Janardhan HP, Saheera S, Jung R, et al. Vascular and lymphatic malformations: perspectives from human and vertebrate studies [J]. Circ Res, 2021, 129(1): 131-135.
[7] De Leacy R, Bageac DV, Manna S, et al. A radiologic grading system for assessing the radiographic outcome of treatment in lymphatic and lymphatic-venous malformations of the head and neck [J]. AJNR Am J Neuroradiol, 2021, 42(10): 1859-1864.
[8] Berenstein A, Bazil MJ, Sorscher M, et al. Percutaneous sclerotherapy of microcystic lymphatic malformations: the use of an innovative gravity-dependent technique [J]. J Neurointerv Surg, 2022, 28: 018526. doi: 10.1136/neurintsurg-2021-018526.
[9] Elluru RG, Balakrishnan K, Padua HM. Lymphatic malformations: diagnosis andmanagement [J]. Semin Pediatr Surg,2014,23(4): 178-185.
[10] Cursiefen C, Chen L, Dana MR, et al. Corneal lymphangiogenesis: evidence, mechanism, and implications for corneal transplant immunology [J]. Cornea, 2003, 22(3): 273-281.
[11] Liersch R, Detmar M. Lymphangiogenesis in development and disease [J]. Thromb Haemost, 2007, 98(2): 304-310.
[12] Bekisz S, Baudin L, Buntinx F, et al. In vitro, in vivo, and in silico models of lymphangiogenesis in solid malignancies [J]. Cancers(Basel), 2022,14(6):1525.
[13] Oliver G. Lymphatic vasculature development [J]. Nat Rev Immunol, 2004,4(1): 35-45.
[14] Luks VL, Kamitaki N, Vivero MP, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA [J]. J Pediatr,2015,166:1048-1054. doi: 10.1016/j.jpeds.2014.12.069.
[15] Zenner K, Jensen DM, Dmyterko V, et al. Somatic activating BRAF variants. cause isolated lymphatic malformations [J]. HGG Adv,2022,3(2):100101.
[16] Martinez-Corral I, Zhang Y, Petkova M, et al. Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation [J]. Nat Commun,2020,11(1):2869.
[17] Kato M, Watanabe S, Iida T, et al. Flow pattern classification in lymphatic malformations by indocyanine green lymphography [J]. Plast Reconstr Surg, 2019,143(3):558e-564e.
[18] Bhatnagar A, Neyaz Z, Singh B, et al. Bleomycin sclerotherapy in massive macrocystic lymphatic malformation: minimal complications with maximum results [J]. J Cutan Aesthet Surg, 2020,13(4):319-325.
[19] 谢义民,陈强,王玲,等. 聚桂醇瘤腔内注射治疗小儿囊性淋巴管瘤[J].中华小儿外科杂志,2017,38(9):704-707. XIE Yimin, CHEN Qiang, WANG Ling, et al. Intratumoral injection of lauromacrogol for children with cyctic lymphangioma [J]. Chinese Journal of Pediatric Surgery,2017,38(9):704-707.
[20] Fuentes S, Delgado D, Marti E, et al. Treatment of lymphatic malformations with OK-432 sclerosis: our experience [J]. Cir Pediatr,2010,23(2):88-91.
[21] Horbach SE, Lokhorst MM, Saeed P, et al. Sclerotherapy for low-flow vascular malformations of the head and neck: a systematic review of sclerosing agents [J]. J Plast Reconstr Aesthetic Surg, 2016, 69:295-304. doi: 10.1016/j.bjps.2015.10.045.
[22] Fernandes S, Yeung P, Heran M, et al. Sclerosing agents in the management of lymphatic malformations in children: a systematic review [J]. J Pediatr Surg, 2022, 57(5):888-896.
[23] Al-Faky YH, Alkatan HM. Histopathological changes of lymphatic malformation after bleomycin injection [J]. Arq Bras Oftalmol, 2022, 21:s0004. doi: 10.5935/0004-2749.20230048.
[24] Cho AL, Kiang SC, Lodenkamp J, et al. Fatal lung toxicity after intralesionalbleomycin sclerotherapy of a vascular malformation [J]. Cardiovasc Intervent Radiol,2020,43(4):648-651.
[25] Blaise S, Charavin-Cocuzza M, Riom H, et al. Treatment of low-flow vascular malformations by ultrasound-guided sclerotherapy with polidocanol foam: 24 cases and literature review [J]. Eur J Vasc Endovasc Surg, 2011,41(3):412-417.
[1] ZHAO Yiyun, HUANG Jingchun, WANG Yuelian, SHAO Shan, SUN Guangping, CUI Enmei, ZHUO Shaoyang, LIU Shaohua. Effects of pingyangmycin combined with sodium hyaluronate on human lymphatic malformation endothelial cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(1): 41-46.
[2] WU Shanbin, XU Hongwei, LIU Hui, LI Bin. Endoscopic injection sclerotherapy performed both by intravariceal and paravariceal injection for esophageal variceal hemorrhage#br# [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(6): 85-89.
[3] WANG Feng-qiang1 , WANG Ai-hua1, YIN Ying-qiu2, WANG Rong3. Effects of dexamethasone on dynamic changes of lung tissue pathology, ultrastructure and levels of TGFβ1 and IL8 in serum of Pingyangmycininduced pulmonary fibrosis in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 27-32.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32 -37 .
[2] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7 -14 .
[3] FU Jieqi, ZHANG Man, ZHANG Xiaolu, LI Hui, CHEN Hong. Molecular mechanism of Toll-like receptor 4 in the aggravation of blood lipid accumulation by inhibiting the peroxisome proliferator-activate receptor γ[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 24 -31 .
[4] SUO Dongyang, SHEN Fei, GUO Hao, LIU Lichang, YANG Huimin, YANG Xiangdong. Expression and mechanism of Tim-3 in animal model of drug-induced acute kidney injury[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 1 -6 .
[5] LONG Tingting, XIE Ming, ZHOU Lu, ZHU Junde. Effect of Noggin protein on learning and memory abilities and the dentate gyrus structure after cerebral ischemia reperfusion injury in mice[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 15 -23 .
[6] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38 -46 .
[7] DING Xiangyun, YU Qingmei, ZHANG Wenfang, ZHUANG Yuan, HAO Jing. Correlation of the expression of insulin-like growth factor II in granulosa cells and ovulation induction outcomes of 84 patients with polycystic ovary syndrome[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 60 -66 .
[8] XIAO Juan, XIAO Qiang, CONG Wei, LI Ting, DING Shouluan, ZHANG Yuan, SHAO Chunchun, WU Mei, LIU Jianing, JIA Hongying. Comparison of diagnostic efficacy of two kinds of thyroid imagine reporting and data systems[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 53 -59 .
[9] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[10] GUO Zhihua, ZHAO Daqing, XING Yuan, WANG Wei, LIANG Leping, YANG Jing, ZHAO Qianqian. Single-stage end-to-end anastomosis in the management of severe cervical tracheal stenosis[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 72 -76 .